Cargando…

Longitudinal Trajectories of Participant- and Study Partner-Rated Cognitive Decline, in Relation to Alzheimer’s Disease Biomarkers and Mood Symptoms

Whereas discrepancies between participant- and study partner-reported cognitive concerns on the Alzheimer’s disease (AD) continuum have been observed, more needs to be known regarding the longitudinal trajectories of participant- vs. study partner-reported concerns, particularly their relationship t...

Descripción completa

Detalles Bibliográficos
Autores principales: Munro, Catherine E., Buckley, Rachel, Vannini, Patrizia, DeMuro, Carla, Sperling, Reisa, Rentz, Dorene M., Johnson, Keith, Gatchel, Jennifer R., Amariglio, Rebecca
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8841868/
https://www.ncbi.nlm.nih.gov/pubmed/35173601
http://dx.doi.org/10.3389/fnagi.2021.806432
_version_ 1784650937192677376
author Munro, Catherine E.
Buckley, Rachel
Vannini, Patrizia
DeMuro, Carla
Sperling, Reisa
Rentz, Dorene M.
Johnson, Keith
Gatchel, Jennifer R.
Amariglio, Rebecca
author_facet Munro, Catherine E.
Buckley, Rachel
Vannini, Patrizia
DeMuro, Carla
Sperling, Reisa
Rentz, Dorene M.
Johnson, Keith
Gatchel, Jennifer R.
Amariglio, Rebecca
author_sort Munro, Catherine E.
collection PubMed
description Whereas discrepancies between participant- and study partner-reported cognitive concerns on the Alzheimer’s disease (AD) continuum have been observed, more needs to be known regarding the longitudinal trajectories of participant- vs. study partner-reported concerns, particularly their relationship to AD biomarkers and mood symptomology. Additionally, it is unclear whether years of in-clinic data collection are needed to observe relationships with AD biomarkers, or whether more frequent, remote assessments over shorter periods of time would suffice. This study primarily sought to examine the relationships between longitudinal trajectories of participant- and study partner-rated cognitive decline and baseline biomarker levels [i.e., amyloid and tau positron emission tomography (PET)], in addition to how mood symptomatology may alter these trajectories of concerns over a 2-year period. Baseline mood was associated with longitudinal participant-rated concerns, such that participants with elevated depression and anxiety scores at baseline had decreasing concerns about cognitive decline over time (fixed estimate = −0.17, 95% CI [−0.29 to −0.05], t = −2.75, df = 457, adj. p = 0.012). A significant interaction between baseline amyloid (fixed estimate = 4.07, 95% CI [1.13–7.01], t = 2.72, df = 353, adj. p = 0.026) and tau (fixed estimate = 3.50, 95% CI [0.95–6.06], t = 2.70, df = 331, adj. p = 0.030) levels was associated with increasing study partner concerns, but not participant concerns, over time. The interaction between amyloid and study partner concerns remained significant when utilizing only the first year of concern-related data collection. Overall, these results suggest that frequent, remote assessment of study partner-reported concerns may offer additional insight into the AD clinical spectrum, as study partners appear to more accurately update their concerns over time with regard to pathology, with these concerns less influenced by participants’ mood symptomatology.
format Online
Article
Text
id pubmed-8841868
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-88418682022-02-15 Longitudinal Trajectories of Participant- and Study Partner-Rated Cognitive Decline, in Relation to Alzheimer’s Disease Biomarkers and Mood Symptoms Munro, Catherine E. Buckley, Rachel Vannini, Patrizia DeMuro, Carla Sperling, Reisa Rentz, Dorene M. Johnson, Keith Gatchel, Jennifer R. Amariglio, Rebecca Front Aging Neurosci Neuroscience Whereas discrepancies between participant- and study partner-reported cognitive concerns on the Alzheimer’s disease (AD) continuum have been observed, more needs to be known regarding the longitudinal trajectories of participant- vs. study partner-reported concerns, particularly their relationship to AD biomarkers and mood symptomology. Additionally, it is unclear whether years of in-clinic data collection are needed to observe relationships with AD biomarkers, or whether more frequent, remote assessments over shorter periods of time would suffice. This study primarily sought to examine the relationships between longitudinal trajectories of participant- and study partner-rated cognitive decline and baseline biomarker levels [i.e., amyloid and tau positron emission tomography (PET)], in addition to how mood symptomatology may alter these trajectories of concerns over a 2-year period. Baseline mood was associated with longitudinal participant-rated concerns, such that participants with elevated depression and anxiety scores at baseline had decreasing concerns about cognitive decline over time (fixed estimate = −0.17, 95% CI [−0.29 to −0.05], t = −2.75, df = 457, adj. p = 0.012). A significant interaction between baseline amyloid (fixed estimate = 4.07, 95% CI [1.13–7.01], t = 2.72, df = 353, adj. p = 0.026) and tau (fixed estimate = 3.50, 95% CI [0.95–6.06], t = 2.70, df = 331, adj. p = 0.030) levels was associated with increasing study partner concerns, but not participant concerns, over time. The interaction between amyloid and study partner concerns remained significant when utilizing only the first year of concern-related data collection. Overall, these results suggest that frequent, remote assessment of study partner-reported concerns may offer additional insight into the AD clinical spectrum, as study partners appear to more accurately update their concerns over time with regard to pathology, with these concerns less influenced by participants’ mood symptomatology. Frontiers Media S.A. 2022-01-31 /pmc/articles/PMC8841868/ /pubmed/35173601 http://dx.doi.org/10.3389/fnagi.2021.806432 Text en Copyright © 2022 Munro, Buckley, Vannini, DeMuro, Sperling, Rentz, Johnson, Gatchel and Amariglio. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Neuroscience
Munro, Catherine E.
Buckley, Rachel
Vannini, Patrizia
DeMuro, Carla
Sperling, Reisa
Rentz, Dorene M.
Johnson, Keith
Gatchel, Jennifer R.
Amariglio, Rebecca
Longitudinal Trajectories of Participant- and Study Partner-Rated Cognitive Decline, in Relation to Alzheimer’s Disease Biomarkers and Mood Symptoms
title Longitudinal Trajectories of Participant- and Study Partner-Rated Cognitive Decline, in Relation to Alzheimer’s Disease Biomarkers and Mood Symptoms
title_full Longitudinal Trajectories of Participant- and Study Partner-Rated Cognitive Decline, in Relation to Alzheimer’s Disease Biomarkers and Mood Symptoms
title_fullStr Longitudinal Trajectories of Participant- and Study Partner-Rated Cognitive Decline, in Relation to Alzheimer’s Disease Biomarkers and Mood Symptoms
title_full_unstemmed Longitudinal Trajectories of Participant- and Study Partner-Rated Cognitive Decline, in Relation to Alzheimer’s Disease Biomarkers and Mood Symptoms
title_short Longitudinal Trajectories of Participant- and Study Partner-Rated Cognitive Decline, in Relation to Alzheimer’s Disease Biomarkers and Mood Symptoms
title_sort longitudinal trajectories of participant- and study partner-rated cognitive decline, in relation to alzheimer’s disease biomarkers and mood symptoms
topic Neuroscience
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8841868/
https://www.ncbi.nlm.nih.gov/pubmed/35173601
http://dx.doi.org/10.3389/fnagi.2021.806432
work_keys_str_mv AT munrocatherinee longitudinaltrajectoriesofparticipantandstudypartnerratedcognitivedeclineinrelationtoalzheimersdiseasebiomarkersandmoodsymptoms
AT buckleyrachel longitudinaltrajectoriesofparticipantandstudypartnerratedcognitivedeclineinrelationtoalzheimersdiseasebiomarkersandmoodsymptoms
AT vanninipatrizia longitudinaltrajectoriesofparticipantandstudypartnerratedcognitivedeclineinrelationtoalzheimersdiseasebiomarkersandmoodsymptoms
AT demurocarla longitudinaltrajectoriesofparticipantandstudypartnerratedcognitivedeclineinrelationtoalzheimersdiseasebiomarkersandmoodsymptoms
AT sperlingreisa longitudinaltrajectoriesofparticipantandstudypartnerratedcognitivedeclineinrelationtoalzheimersdiseasebiomarkersandmoodsymptoms
AT rentzdorenem longitudinaltrajectoriesofparticipantandstudypartnerratedcognitivedeclineinrelationtoalzheimersdiseasebiomarkersandmoodsymptoms
AT johnsonkeith longitudinaltrajectoriesofparticipantandstudypartnerratedcognitivedeclineinrelationtoalzheimersdiseasebiomarkersandmoodsymptoms
AT gatcheljenniferr longitudinaltrajectoriesofparticipantandstudypartnerratedcognitivedeclineinrelationtoalzheimersdiseasebiomarkersandmoodsymptoms
AT amarigliorebecca longitudinaltrajectoriesofparticipantandstudypartnerratedcognitivedeclineinrelationtoalzheimersdiseasebiomarkersandmoodsymptoms